Sector News

Clinical trials firm BioClinica explores sale: sources

May 27, 2016
Life sciences

BioClinica Inc, a U.S. pharmaceutical contract research organization owned by buyout firm JLL Partners, is exploring a sale that could value it at as much as $1.3 billion, including debt, according to people familiar with the matter.

The Newtown, Pennsylvania-based company has hired investment bank Jefferies LLC to run an auction for the company, the people said this week, declining to be identified because the discussions are private.

JLL Partners declined to comment. Jefferies and BioClinica did not immediately respond to requests for comment.

The sale process highlights a wave of dealmaking activity that has overtaken the pharmaceutical services sector in recent months, with some of the largest players, including InVentiv Health Inc and Capsugel Inc, exploring an outright sale or an initial public offering, according to reports by Reuters.

Last year, another JLL Partners investment, Patheon, announced plans for an IPO. It is one of the largest contract manufacturing companies in the pharmaceutical industry.

In 2013, JLL Partners acquired BioClinica, which was at the time a publicly traded company, for an equity value of $123 million.

In the ensuing years, the buyout firm rapidly scaled up BioClinica through a series of acquisitions, including most recently with the purchase of specialty clinical trial services firm Synowledge.

BioClinica’s profits have grown as a result, with annual earnings before interest, taxes depreciation and amortization now approaching $100 million, according to the sources.

BioClinica assists pharmaceutical companies in clinical trials, and has expertise in technologies that focus on clinical research data and analytics. It supports over 17,000 clinical trial sites in 90 countries.

By Carl O’Donnell

Source: Reuters

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 10, 2021

Merck to acquire German contract development company AmpTec

Life sciences

The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.

January 10, 2021

Goodbye pill, hello science: Pfizer debuts redesigned logo with double helix

Life sciences

It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.

January 10, 2021

Fujifilm triples down on viral vector manufacturing with new $40M Boston site

Life sciences

The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.

Send this to a friend